Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether MustGrow Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MustGrow Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
MustGrow Biologics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
MustGrow Biologics's earnings available for a low price, and how does
this compare to other companies in the same industry?
MustGrow Biologics has negative assets, we can't compare the value of its assets to the CA Chemicals industry average.
Take a look at our analysis of MGRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MustGrow Biologics's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MustGrow Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Chemicals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare MustGrow Biologics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare MustGrow Biologics's earnings growth to the Canada market average as no estimate data is available.
Unable to compare MustGrow Biologics's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if MustGrow Biologics is high growth as no earnings estimate data is available.
Unable to determine if MustGrow Biologics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
MustGrow Biologics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
MustGrow Biologics's finances.
The net worth of a company is the difference between its assets and liabilities.
MustGrow Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
MustGrow Biologics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
MustGrow Biologics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
MustGrow Biologics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Corey J. Giasson, MBA, B.Sc., serves as President at MustGrow Biologics Corp. and serves as its Chief Executive Officer and Director since March 15, 2018. Mr. Giasson had been the Chief Financial Officer of MustGrow Biologics Corp. since March 15, 2018 till December 17, 2018. He served as the President and Chief Executive Officer of Rallyemont Energy Inc. Mr. Giasson served as the Chief Executive Officer, President and Promoter of Kenna Capital Corp. until April 2012. Mr. Giasson was an independent consultant of PanWestern Energy Inc., Infrastructure Materials Corp., and Anglo Potash Ltd. He served as a Vice President of Business Development and Investor Relations at Anglo Potash Limited (also known as Anglo Minerals Ltd). since May 1, 2007. Mr. Giasson was employed by PotashCorp, the world's largest potash producer in Saskatoon, Saskatchewan, where he held the title of Manager, Market Research. Mr. Giasson was employed for three years as a business analyst at an accounting and business advisory firm where he assisted in consulting primary and secondary agriculture producers. He served as a Director of Rallyemont Energy Inc. He served as a Director of Kenna Resources Corp. from September 25, 2009 to July 23, 2014. Mr. Giasson holds an MBA and a B.Sc. in Agriculture Economics from the University of Saskatchewan.
Insufficient data for Corey to compare compensation growth.
Corey's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the MustGrow Biologics management team is less than 2 years, this suggests a new team.
CFO & Corporate Secretary
COO & Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the MustGrow Biologics board of directors is less than 3 years, this suggests a new board.
Board of Directors
COO & Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by MustGrow Biologics individual insiders in the past 3 months.
Is MustGrow Biologics (CNSX:MGRO) A Risky Investment?
CNSX:MGRO Historical Debt, July 31st 2019 How Strong Is MustGrow Biologics's Balance Sheet? … This surplus suggests that MustGrow Biologics has a conservative balance sheet, and could probably eliminate its debt without much difficulty. … Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow.
MustGrow Biologics Corp., a technology development company, develops natural biopesticide products from mustard seed. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. The company was incorporated in 2014 and is headquartered in Saskatoon, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.